HK inno.N has published the results of phase 3 clinical trial of gastroesophageal reflux disease (GERD) drug on gastric ulcers, K-CAB tablets, in the medical journal Alimentary Pharmacology & Therapeutics (AP&T).

The clinical trial was conducted for eight weeks, with 306 gastric ulcer patients diagnosed at multiple centers in Korea. The researchers assigned 102 patients with a randomized and double-blind method to each cohort with 50 milligrams K-CAB, 100 milligrams of K-CAB, and 30 milligrams of Lansoprazole.

HK inno.N has published the phase 3 clinical trial results of its gastroesophageal reflux disease (GERD) drug on gastric ulcers, K-CAB tablets, in the medical journal Alimentary Pharmacology & Therapeutics (AP&T). (HK inno.N)

In the study, cohorts with 50 and 100 milligrams of K-CAB tablets showed superior therapeutic effect and safety in treating gastric ulcers than the group administered with 30 milligrams of Lansoprazole.

“The efficacy and safety of the new drug K-CAB tablet, one of the potassium competitive acid blocker (P-CAB) series for GERD, has received global recognition with the publication of our study results,” an official of HK inno.N said. “We will continue to try expanding the drug’s indications and conduct differentiated research to develop K-CAB as a new global drug in Korea.”

The company launched K-CAB in Korea in 2019 as a GERD treatment based on a P-CAB. It indicates treating erosive and non-erosive GERD, gastric ulcer, and helicobacter pylori eradication.

The study, titled, “Randomized clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or Lansoprazole in the treatment of gastric ulcer,” was published on AP&T with an impact factor of 7.515.

Copyright © KBR Unauthorized reproduction, redistribution prohibited